ABSTRACT
INTRODUCTION
In the UK, initiatives such as practice-based commissioning have encouraged the development of GPs with special interests to deliver specialist services in the community. 1 The introduction of GP commissioning and transfer of the NHS primary care budget to GP consortia, 2 has been seen as an opportunity to change the arrangements for prescribing specialist drugs and providing new services within primary care to avoid patients attending hospital clinics. 3 Specialist drugs are those which have significant pharmacological complexity and/or rarity of use making prescribing in primary care relatively uncommon. 4 In 1991, the NHS Management Executive outlined core principles and clinical responsibilities associated with prescribing at the primary and secondary care interface including the use of protocols to support GPs prescribe specialist drug under shared care agreements. 1 Local advisory lists were made available to support GPs in managing shifts in prescribing from secondary care to primary care with medicines grouped as hospital only (red), appropriate for shared care or restricted use (amber), and for GP use and initiation (green). 5 NHS Prescription Services provides prescribing, financial and drug information to managing organisations within the NHS in England. In 2006-07 1.3 million prescriptions for specialist drugs were issued by GPs, 6 rising to 1.7 million in 2014-15, 7 with the most frequently prescribed specialist drugs (29. drugs from primary care to secondary care. 8 The specialist drugs list maintained by NHS Prescription Services is not exhaustive and does not specify which drugs should be classed as red or amber. This responsibility rests with local organisations such as area prescribing committees which can lead to regional variation in which specialist drugs are recommended for use only in secondary care or those suitable to 4 | P a g e be prescribed by GPs under shared care arrangements (in the form of local advisory lists). In 2014-15 41.89% of prescriptions for specialist drugs issued by GPs in England were classified as red that is hospital only based on the traffic light classification used across North West London. 9 Shared care protocols are developed and approved by local area prescribing commitees such as the Midlands Therapeutic Advisory Committee. 10 Shared care protocols must be patient specific and clarify individual roles and responsibilities, medicine details, patient monitoring and circumstances where treatment should be modified or stopped. 1 One UK survey has reported on the production of 321 shared care protocols that have described 99 different drugs or treatments. 11 A range of factors influence GP decision making in prescribing specialist drugs including shared care arrangements and the influence of local advisory lists. 12 GP dissatisfaction with arrangements for prescribing specialist drugs, 13 and a lack of GP involvement in the development of shared care protocols has been reported. 11, 14 Barriers to GP acceptance of shared care protocols have included cost shifting, 11, 13 training, 15 20 clinician performance, 21 and drug dosing and therapeutic response. 22 However limitations include a lack of evidence in improving safety measured by medical errors or adverse events, 23 and in patient outcomes. 24, 25 Poor usability has been cited as a core barrier to CDSS adoption, with system designers encouraged to apply common standards based on human-computer interaction methods and user-centred design. 26 In the UK, commercial CDSS that supports cost effective prescribing is widely available to
GPs. 27, 28 In a recent development CDSS has become available to support GPs in implementing medicines optimisation. 29 Such systems are able to provide locally authored messaging platforms to provide drug information and safety alerts to prescribers including links to local advisory lists known as traffic light classifications and shared care protocols.
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However, in a recent review, 30 the impact of one of these systems, 28 has been described as limited compared to other existing cost effective prescribing initiatives with drawbacks including alert content, and a lack of GP control. No published study has evaluated the potential for a CDSS to support GPs prescribe specialist drugs. In the current study software engineering and human factors methods were used to identify a potential operating model for a CDSS to support GPs in the safety and quality of specialist drug prescribing.
METHODS

Studies Design
A review of the published literature of CDSSs in the UK identified four stakeholder groups who would provide insight into the requirements of a potential CDSS that could support GPs during the process of prescribing specialist drugs. An exploratory study was initially undertaken using face-to-face interviews with 12 key informants which were all conducted by the lead trained research pharmacist.The key informants were GPs (n = 2), NHS IT managers (n = 2), secondary care clinicians (n = 4) and representatives from the CDSS industry / GP clinical system suppliers (n = 4). Secondary care clinicians with a specialist knowledge of drugs an immunosuppression in renal transplantation were invited to participate. UK-based commercial CDSS and GP clinical system suppliers were approached while London-based IT managers and GPs were invited. These interviews were used to gain an understanding of current usage and characteristics of CDSSs available within primary care and to explore the feasibility of incorporating a CDSS to support GPs in the prescribing of specialist drugs. Interview schedules were designed for each stakeholder group and used as a topic guide. During each interview emerging themes were used to formulate further questions. Interviews were recorded, transcribed verbatim and analysed using framework analysis, 31 supported by NVivo (Version 10). The resulting data was reviewed by members of the research team and analysed for emerging key themes across the interviews.
In order to further understand the actual needs and requirements of GPs as end users of a potential CDSS, an observational study with GPs was conducted. In total nine GPs who were users of the three major UK GP clinical systems (EMIS, Vision and SystmOne) were purposively 32 selected to participate. The selection took into account the results from the key informant interviews and factors such as GP availability, willingness to participate and demographic characteristics. Six of the GPs were partners whilst three were salaried GPs.
The GPs qualified between 2001 and 2013. All of the GPs described themselves as having either a medium or high IT aptitude. In this observational study the lead researcher discussed and observed the participants perform pre-defined case studies and took written notes on performed tasks and workflows. A research guide was designed to include specific pre-6 | P a g e determined questions about computer use including CDSSs both during and outside patient consultation with emerging themes used to formulate further questions. Case scenarios were developed from the results of the key informant interviews with particular emphasis on the use, quality and availability of shared care protocols. The case scenarios were observed and discussed with each GP depicting situations where patients presented prescriptions for specialist drugs (for example tacrolimus) or these were requested by the hospital, identifying the steps taken by each GP to accept or decline prescribing.
Data Analysis
Data from the observations and discussions were used to develop activity diagrams representing how GPs conducted their work, used their computers both during and outside patient consultation, and how they dealt with the specialist drug prescribing case scenarios.
Activity diagrams are often organised as swim lanes to identify who or what is responsible for a specific task or activity, 33 and have been used to model workflow patterns involved in prescription writing and management within primary care settings. 34 A hierarchical task analysis (HTA) was performed to describe in detail the process GPs used to prescribe specialist drugs. HTA models tasks as hierarchies of goals and sub-goals, with plans showing how sub-goals should be undertaken. 35 Error analysis based on SHERPA 36 was applied to the HTA sub-tasks identifying possible errors, consequence, recovery, probability of occurrence and remedial action or design solution.
RESULTS
Exploratory Study
The primary themes that emerged from the exploratory interviews were safety, IT systems and costs, which are shown in Box 1 with secondary themes and emerging key criteria. In total 25
CDSSs were identified of which nine were active systems (provide patient-specific advice), and 16 passive (clinicians need to request the information, not patient-specific). The CDSSs supported a wide range of activities including prescribing, drug information and disease management. All of the GP clinical systems provided active CDSSs to support prescribing via drug alerts or warnings and reminders or prompts to support the Quality and Outcomes
Framework (QOF) component of the national General Medical Services (GMS) contract. In terms of specialist drugs and shared care protocols, mixed experiences were described by the GPs and secondary care clinicians, with specific concerns from a GP perspective in relation to safety, clinical responsibility to prescribe, and in the availability and quality of shared care protocols (Box 2). The concept of developing a CDSS to support GPs prescribe specialist drugs was acknowledged as beneficial by all 12 key informants. Enablers and barriers to CDSS development were identified including a number of potential operating and funding 7 | P a g e models (see Box 2) . Key enablers included multi-user access, active alerting, ease of use, joint development and implementation, patient involvement, data quality and functionality, and the use of existing systems and frameworks. Key barriers included security and regulation, implementation, integration and data quality and addressing the needs of end users.
Activity aiagram and hierarchical task analysis
GPs described their actions to the case scenarios, deciding whether or not to accept clinical responsibility for prescribing a specialist drug. Figure 1 displays the activity diagram representing their decision making process. The GPs described limited functionality within each GP clinical system to support the prescribing of specialist drugs. All GPs highlighted the importance of adding simple alerts/reminders to the patient's electronic health record (EHR)
to indicate that the patient was treated with a specialist drug or that a shared care protocol should be followed. Additional needs included restricting drug quantities and creating tasks such as recall to ensure patients were seen on a regular basis. Where shared care protocols were available, all GPs reported they should be scanned and added to the patient's EHR. An additional problem identified was the reliability of administrative staff to scan letters or communications from hospitals. Although the GPs found the use of the clinical systems quick and simple, navigating the systems to locate a shared care protocol was not straightforward (for example if the scanned letters were not filed by speciality they were difficult to locate).
HTA was applied to the actual task of prescribing specialist drugs and is shown in Box 3. Key steps undertaken were to open the patient's EHR and to familiarise themselves with patient's clinical history before reviewing the request to prescribe a specialist drug. GPs checked if the specialist drug was 'hospital only' or whether it could be prescribed by using a shared care
protocol. These checks were made by locating and referring to a traffic light classification of specialist drugs. Although CDSS providing support at the point of prescribing was available e.g. ScriptSwitch ®, none of the GPs referred to this specific functionality during the decision making process.
Errors involved in prescribing specialist drugs
The SHERPA analysis demonstrated that although the specific task of prescribing was relatively simple in terms of the number of steps required to complete the task, the potential for error was considerable (Boxes 4 and 5). The potential errors that could occur were either cited by the individual GP (GP1 to GP9) or identified by the research team during data analysis. The underlying problem faced by the GPs was dealing with a paper based communication system with secondary care. The risk of prescribing specialist drugs in an unsafe manner was increased due to lack of functionality within all the GP clinical systems and time constraints particularly where a decision needed to be made during a consultation.
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To resolve these issues GPs relied on other staff to provide advice and information. In many cases the next opportunity to resolve such problems was when a further prescription was requested by the patient. The predominant theme that emerged from the SHERPA analysis was the high frequency of error mode R1 ("Information not obtained") because information required by the GP was not readily available. The potential adverse outcome was that a GP could inadvertently prescribe a specialist drug classified as hospital only, or prescribe one without reference to an appropriate shared care protocol. In addition, in 11 of the 20 task steps an error rated as a high probability of occurrence could occur. The fundamental problems described by the GPs related to lack of awareness or availability of either the traffic light list or shared care protocols. In addition, where shared care protocols were required, a major obstacle was locating them in either a paper or electronic format, particularly during patient consultations.
It was evident throughout the whole process that GP clinical systems and CDSSs were not able to provide full solutions to the problems described by the GPs. One remedial solution was to manually add simple alerts or reminders to the patients' EHR. These alerts allowed free text to be added to a pop up box informing each user of key messages related to prescribing of specialist drugs, for example checking the shared care protocol or requirements for regular blood tests. Other interventions described were manual tasks to contact and liaise with a range of individuals such as other GPs, primary care pharmacists and clinical teams within secondary care. Application of both HTA and SHERPA identified a potential operating model for a CDSS to support GPs in prescribing specialist drugs. Box 6 describes a HTA of this proposed model demonstrating how GPs could potentially safely prescribe a specialist drug in primary care.
DISCUSSION
Summary
Previous studies have identified concerns from GPs in prescribing specialist drugs and in the use of shared care protocols ,11-13 Difficulties have included lack of awareness or access to either local traffic light classification lists or shared care protocols .11 Furthermore, CDSSs have been reported to appear too late during patient consultations, by which time GPs had already made a decision around treatment options. 37 In the current study it was identified that the lack of specific functionality within GP clinical systems (EMIS, Vision, SystmOne) including CDSSs, adversely affected the GPs' ability to resolve problems associated with prescribing of specialist drugs. To the authors' knowledge this is the first study, to perform a detailed analysis of the tasks and potential errors (HTA and SHERPA) during the prescribing process in the three major GP clinical systems available in the UK. This detailed analysis enabled the identification 9 | P a g e of specific weaknesses and potential errors with current systems that have not been previously identified, and to propose possible solutions in the form of a potential operating model for a CDSS to support GPs in prescribing specialist drugs.
Strengths and Limitations
The strength in thiswork resides in its use of human factors methods (HTA and SHERPA) for analysing the GPs tasks and workflows in prescribing specialist drugs. Using human factors techniques and risk assessment methods are encouraged for designing healthcare interventions. 38, 39 Nevertheless, this is the first study that has analysed the prescribing of specialist drugs by GPs using these methods. Participants used the three major GP clinical systems available in the UK. This ensures that the findings are relevant to the majority of GP practices. However, the recruitment process of the participants was not optimal as two of the GPs (GP1, GP2) participated in both the exploratory study and the main study, whilst GP3
was involved in the piloting of the exploratory study and also participated in the main study.
All of the GPs worked within a single clinical commissioning group (CCG), were purposively selected and were known to the lead researcher which may have introduced bias. All of the 
Comparison with Existing Literature
Although healthcare has increased the awareness of retrospective safety assessment techniques such as root cause analysis, the use of predictive safety assessment techniques (such as SHERPA, Failure Modes and Effect Analysis) is limited and there is a need to adopt more proactive and rigorous approaches. 40, 41 This work is novel as no previous study has applied HTA and SHERPA to inform a CDSS for prescribing specialist drugs. Previously reported use of HTA with or without SHERPA in the UK has been primarily limited to the study of endoscopic surgery, 42 diagnosis, 43 drug administration, 44 and anaesthesia use.
46
Implications for research
The results from this study have highlighted that despite the availability of CDSSs and other functionality within GP clinical systems, safety concerns remain with the use of specialist drugs prescribed by GPs in primary care. Designing a CDSS that considers the needs of GPs, their current workflow, and their decision making process has the potential to both facilitate the prescribing of specialist drugs and decrease the associated risks with prescribing errors.
Designing and evaluating with GPs a CDSS prototype, based on the authors' operating model could be a meaningful step in improving the current prescribing process. In addition, further research could investigate how GP clinical systems and community pharmacy systems could incorporate active hard stops to alert users when hospital only drugs are prescribed. 
C1
Failure by GP to check the traffic light list (GP1, GP3, GP4, GP7)
A hospital only specialist drug is prescribed by the GP At next request for prescription (3.1) Community pharmacist informs GP that a hospital only drug has been prescribed.
Med ium Screen alert when prescribing
Design Solution: The GP clinical system to automatically alert the GP that this is a hospital only drug, not to prescribe and to automatically refer back to the hospital i.e. a hard stop.
Design Solution: The GP clinical system to enable a search of a drug and see its attributes i.e. "hospital only"
Design Solution: The pharmacy computer system to automatically alert the pharmacist that this is a hospital only drug and not to be issued in primary care and to refer back to the GP
R1
Traffic light list is not available at the practice (paper list) (GP1) 
Med ium
Details of local CCG pharmaceutical adviser to be made available either at the GP practice and or within the GP clinical system *medicines management team refers to the NHS pharmacist led management framework that supports and advises local NHS commissioning groups, GPs, and other stakeholder groups, although actual arrangements may differ locally CCG = clinical commissioning group. EHR = electronic health record. SHERPA = systematic human error reduction and prediction approach. Module" and prescribes a "hospital only" drug or prescribes a drug without reference to the shared care protocol, the GP clinical system will automatically alert the GP
